Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jan 12, 2023 8:24pm
94 Views
Post# 35219993

RE:RE:RE:RE:RE:RE:RE:Insiders

RE:RE:RE:RE:RE:RE:RE:Insiders
bluemoons20 wrote: Very interesting.  Is there some interest in this possibility now??

I  seem to recall  suggesting this a few months ago  and  received no response of any kind to the suggestion.


Yes  , a real possibility  and  rather  than get the  $5  someone suggested  recently  , Existing shareholders  may  get  5  cents  per share on a good  day.

GLTA


bluemoons20
There are a couple of scenarios at play. Firstly with the 10+ insiders controlling the company if they choose to take it private the share buyout price will not be $.05. I suspect if it happened now it would be in the range of $.25 or above.  I am not sure on what Canadian securities rules apply when companies are taken from publicly traded to private.
Secondly the other scenario is Shiseido sees the hand writing on the all and either agrees to a deal to remain partnered with Replicel with some monetary compensation or either buys Replicel out.  
If it is compensation I can't imagine it would be more than $5,000,000.  If it is a buyout I am guessing it would an offer of on the low side at $1.00 per share or on the high side possibly $3.00 per share.
I  haven't a clue how these 10+ insiders would react to either of these two scenarios. 

<< Previous
Bullboard Posts
Next >>